XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy

J Transl Med. 2021 Oct 9;19(1):421. doi: 10.1186/s12967-021-03098-5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinase Kinases
  • Humans
  • Immunotherapy
  • Kelch-Like ECH-Associated Protein 1 / genetics
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • Mutation / genetics
  • NF-E2-Related Factor 2*
  • Protein Serine-Threonine Kinases / genetics

Substances

  • KEAP1 protein, human
  • Kelch-Like ECH-Associated Protein 1
  • NF-E2-Related Factor 2
  • Protein Serine-Threonine Kinases
  • STK11 protein, human
  • AMP-Activated Protein Kinase Kinases